These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21715210)

  • 1. [Pathogen inactivation processes applicable to cellular products: the Canadian perspective].
    Delage G
    Transfus Clin Biol; 2011 Aug; 18(4):485-7. PubMed ID: 21715210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
    Canellini G; Wasserfallen JB; Tissot JD
    Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen Reduction Technology in Transfusion: Where Do We Stand?
    Khurshid M; Moiz B
    J Coll Physicians Surg Pak; 2015 Nov; 25(11):779-80. PubMed ID: 26577959
    [No Abstract]   [Full Text] [Related]  

  • 5. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogen inactivation technologies: a complex but necessary debate].
    Andreu G; Cazenave JP; Garraud O; Lefrère JJ
    Transfus Clin Biol; 2011 Aug; 18(4):443. PubMed ID: 21783399
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogen reduction for platelets: available techniques and recent developments].
    Andreu G
    Transfus Clin Biol; 2011 Aug; 18(4):444-62. PubMed ID: 21724440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on the current opinions on blood components safety/efficacy.
    Seghatchian J
    Transfus Apher Sci; 2006 Jun; 34(3):241-2. PubMed ID: 16807111
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining "adequate" pathogen reduction performance for transfused blood components.
    Goodrich RP; Custer B; Keil S; Busch M
    Transfusion; 2010 Aug; 50(8):1827-37. PubMed ID: 20374558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The risk of substitution therapy with blood and blood products].
    Baumgarten R
    Z Arztl Fortbild (Jena); 1994 Jan; 88(1):3-4. PubMed ID: 8154136
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transfusion of blood and products derived from blood].
    Wautier JL
    Rev Prat; 1999 Feb; 49(4):409-13. PubMed ID: 10319693
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving blood safety and patient outcomes with pathogen reduction technology.
    Goodrich RP; Ettinger A; Radziwon PM; Rock G
    Transfus Apher Sci; 2011 Dec; 45(3):229-38. PubMed ID: 22078570
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pathogen reduction for platelets: a debate].
    Moncharmont P; Py JY
    Transfus Clin Biol; 2011 Aug; 18(4):498-501. PubMed ID: 21715209
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pathogen reduction: a clinician view].
    Socié G
    Transfus Clin Biol; 2011 Aug; 18(4):491-2. PubMed ID: 21715208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.